LGALS9 and neoplasm: On the other hand, Okoye and colleagues recently studied Gal-9 expression in peripheral and tumour-infiltrating CD4+ and CD8+ T cells in virus-associated solid tumours and discovered that its expression defines dysfunctional T cells with impaired effector capacities, indicating poor response to anti-PD-L1 immunotherapy (42).